PD14 - Non-interventional 2-year study of sublingual immunotherapy in children and adolescents with allergic rhinoconjunctivitis caused by grass pollen
© Karagiannis et al; licensee BioMed Central Ltd. 2014
Published: 28 February 2014
The aim of this non-interventional study was to document the impact of a sublingual allergen immunotherapy (AIT) with Oralair 5-grass pollen tablets (Stallergenes, France) on symptom severity, use of symptomatic medication and tolerability in patients with grass pollen-induced allergic rhinoconjunctivitis (RC) over 2 years of routine medical practice treatment. This poster focuses on the subgroups of children (4-11 yrs) and adolescents (12-17 yrs).
This prospective, open, non-controlled, non-interventional, multicenter study was conducted from September 2010 to October 2012 in Germany. Overall 1.482 patients (248 children (16.9%), 201 adolescents (13.7%)) participated in the study.
The patients rated their symptoms as a combined score of severity (scale: 0 [none] – 3 [severe]) and frequency (scale: 0 [none] – 4 [very often]). In the combined RC score, the severity of rhinitis and conjunctivitis were pooled (scale: 0 [none] – 6 [severe]).
During the season preceding AIT treatment 88/ 85% of children/ adolescents had used symptomatic medication. This rate dropped to 57/ 56% (1st season) and to 48/ 40% (2nd season). Likewise the RC score decreased from 4.10/ 4.05 to 1.93/ 1.97 (1st year) and to 1.39/ 1.39 (2nd year).
An improvement in health status after two years of treatment was documented by 96/ 97%.
Adverse events occurred in 17.7/ 20.2% over two years of treatment. The incidence of non-fatal serious adverse events was 1.2/ 0.0%.
At the end of the 2nd season, 96/ 97% evaluated the tolerability of the 5-grass pollen tablets as very good or good.
For the group of monoallergic children/ adolescents, the RC score was reduced from 4.05/ 3.63 to 1.95/ 1.85 (1st year) to 1.29/ 1.10 (2nd year). The RC score in polyallergic children/ adolescents decreased from 4.09/ 4.17 to 1.94/ 2.03 (1st year) to 1.46/ 1.50 (2nd year).
Based on the study results, AIT with Oralair 5-grass pollen tablets was well tolerated by children and adolescents in routine medical practice. All symptom scores and the symptomatic medication use were reduced significantly after one and two years under treatment with Oralair 5-grass pollen tablets compared to the season preceding AIT. Polyallergic children and adolescents benefited as much from AIT as the monoallergic ones.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.